Coagulation factor XI improves host defence during murine pneumonia-derived sepsis independent of factor XII activation

Summary

Bacterial pneumonia, the most common cause of sepsis, is associated with activation of coagulation. Factor XI (FXI), the key component of the intrinsic pathway, can be activated via factor XII (FXII), part of the contact system, or via thrombin. To determine whether intrinsic coagulation is involved in host defence during pneumonia and whether this is dependent on FXII activation, we infected in parallel wild-type (WT), FXI knockout (KO) and FXII KO mice with two different clinically relevant pathogens, the Gram-positive bacterium Streptococcus pneumoniae and the Gram-negative bacterium Klebsiella pneumoniae, via the airways. FXI deficiency worsened survival and enhanced bacterial outgrowth in both pneumonia models. This was accompanied with enhanced inflammatory responses in FXI KO mice. FXII KO mice were comparable with WT mice in Streptococcus pneumoniae pneumonia. On the contrary, FXII deficiency improved survival and reduced bacterial outgrowth following infection with Klebsiella pneumoniae. In both pneumonia models, local coagulation was not impaired in either FXI KO or FXII KO mice. The capacity to phagocytose bacteria was impaired in FXI KO neutrophils and in human neutrophils where activation of FXI was inhibited. Deficiency for FXII or blocking activation of FXI via FXIIa had no effect on phagocytosis. Taken together, these data suggest that FXI protects against sepsis derived from Streptococcus pneumoniae or Klebsiella pneumoniae pneumonia at least in part by enhancing the phagocytic capacity of neutrophils by a mechanism that is independent of activation via FXIIa.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Factor XI - factor XII - Klebsiella pneumoniae - Streptococcus pneumoniae - pneumonia

• References

• 1 Angus DC, Linde-Zwirble WT, Lidicker J. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
• 2 Lagu T, Rothberg MB, Shieh MS. et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40: 754-761.
• 3 Vincent JL, Rello J, Marshall J. et al. International study of the prevalence and outcomes of infection in intensive care units. J Am Med Assoc 2009; 302: 2323-2329.
• 4 van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumo-coccal pneumonia. Lancet 2009; 374: 1543-1556.
• 5 Munoz-Price LS, Poirel L, Bonomo RA. et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-796.
• 6 Levi M, van der Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost 2015; 41: 9-15.
• 7 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114: 2367-2374.
• 8 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (02) S26-S34.
• 9 Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13: 34-45.
• 10 van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care 2008; 12 (06) S3.
• 11 Wuillemin WA, Fijnvandraat K, Derkx BH. et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemost 1995; 74: 1436-1441.
• 12 van Gorp EC, Minnema MC, Suharti C. et al. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol 2001; 113: 94-99.
• 13 Minnema MC, Pajkrt D, Wuillemin WA. et al. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood 1998; 92: 3294-3301.
• 14 Bouma BN, Griffin JH. Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 1977; 252: 6432-6437.
• 15 Gailani D, Broze Jr. GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
• 16 Kravtsov DV, Matafonov A, Tucker EI. et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-458.
• 17 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-7358.
• 18 von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-3042.
• 19 Nickel KF, Renne T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130: S78-S83.
• 20 Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
• 21 Levi M, Schultz MJ, Rijneveld AW. et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31 (04) S238-S242.
• 22 Schultz MJ, Haitsma JJ, Zhang H. et al. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia--a review. Crit Care Med 2006; 34: 871-877.
• 23 Gailani D, Lasky NM, Broze Jr. GJ. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997; 08: 134-144.
• 24 Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-1010.
• 25 de Stoppelaar SF, van t V, Claushuis TA. et al. Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood 2014; 124: 3781-3790.
• 26 Hommes TJ, Hoogendijk AJ, Dessing MC. et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) improves host defence in pneumococcal pneumonia. J Pathol 2014; 233: 357-367.
• 27 Achouiti A, Vogl T, Urban CF. et al. Myeloid-related protein-14 contributes to protective immunity in gram-negative pneumonia derived sepsis. PLoS Pathog 2012; 08: e1002987.
• 28 de Stoppelaar SF, vant Veer C, Van Den Boogaard FE. et al. Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice. Thromb Haemost 2013; 110: 582-592.
• 29 Zeerleder S, Zwart B, Wuillemin WA. et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003; 31: 1947-1951.
• 30 Kager LM, Weehuizen TA, Wiersinga WJ. et al. Endogenous alpha2-antiplasmin is protective during severe gram-negative sepsis (melioidosis). Am J Respir Crit Care Med 2013; 188: 967-975.
• 31 Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 09: 671-675.
• 32 van Montfoort ML, Knaup VL, Marquart JA. et al. Two novel inhibitory anti-human factor XI antibodies prevent cessation of blood flow in a murine venous thrombosis model. Thromb Haemost 2013; 110: 1065-1073.
• 33 van Lieshout MH, Scicluna BP, Florquin S. et al. NLRP3 and ASC differentially affect the lung transcriptome during pneumococcal pneumonia. Am J Respir Cell Mol Biol 2014; 50: 699-712.
• 34 Itakura A, Verbout NG, Phillips KG. et al. Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes. J Leukoc Biol 2011; 90: 923-927.
• 35 Porto BN, Stein RT. Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?. Front Immunol 2016; 07: 311.
• 36 Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100: 158-173.
• 37 van Lieshout MH, Anas AA, Florquin S. et al. Hematopoietic but not endothelial cell MyD88 contributes to host defense during gram-negative pneumonia derived sepsis. PLoS Pathog 2014; 10: e1004368.
• 38 Henderson LM, Figueroa CD, Muller-Esterl W. et al. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 1994; 84: 474-482.
• 39 Luo D, Szaba FM, Kummer LW. et al. Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis. Infect Immun 2012; 80: 91-99.
• 40 Tucker EI, Gailani D, Hurst S. et al. Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis 2008; 198: 271-274.
• 41 Luo D, Szaba FM, Kummer LW. et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. J Immunol 2011; 187: 1866-1876.
• 42 Gentry PA, Ross ML. Coagulation factor XI deficiency in Holstein cattle: expression and distribution of factor XI activity. Can J Vet Res 1994; 58: 242-247.
• 43 Rijneveld AW, Weijer S, Bresser P. et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725-1730.
• 44 Van Den Boogaard FE, Brands X, Schultz MJ. et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 09: 122-132.
• 45 Stroo I, Yang J, de Boer JD. et al. Factor XI deficiency enhances the pulmonary allergic response to house dust mite in mice independent of factor XII. Am J Physiol Lung Cell Mol Physiol 2017; 312: L163-L171.
• 46 Cheng Q, Zhao Y, Lawson WE. et al. The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice. Blood 2005; 106: 3055-3057.
• 47 Maas C, Meijers JC, Marquart JA. et al. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci USA 2010; 107: 9083-9087.
• 48 Tucker EI, Verbout NG, Leung PY. et al. Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis. Blood 2012; 119: 4762-4768.
• 49 de Pont AC, Moons AH, de JE. et al. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost 2004; 02: 65-70.
• 50 de Jonge E, Dekkers PE, Creasey AA. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.